Systemic Immune-Inflammation Index and Mortality in Testicular Cancer: A Systematic Review and Meta-Analysis

Salazar-Valdivia F.E.; Valdez-Cornejo V.A.; Ulloque-Badaracco J.R.; Hernandez-Bustamante E.A.; Alarcón-Braga E.A.; Mosquera-Rojas M.D.; Garrido-Matta D.P.; Herrera-Añazco P.; Benites-Zapata V.A.; Hernandez A.V. · Diagnostics (2023) · DOI: 10.3390/diagnostics13050843

Resumen

The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3–8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53–6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.

Instituciones: Universidad Peruana de Ciencias Aplicadas; Universidad San Ignacio de Loyola; Universidad Privada San Juan Bautista; Universidad Privada del Norte